outcomes of ven-based regimens in cll/sll following intolerance or progression on covalent btki's
Published 8 months ago • 351 plays • Length 2:26Download video MP4
Download video MP3
Similar videos
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
1:19
outcomes of cll patients following treatment with a covalent btk and bcl2 inhibitor
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
1:24
sequencing of btk inhibitors in cll
-
1:21
clinical characteristics and outcomes of the double refractory cll/sll patient population
-
2:53
considering the sequencing of covalent and non-covalent btk inhibitors in cll
-
8:57
outcomes of sct in t-all and t-lbl
-
2:08
the differences in outcomes and treatment in cll patients with mutated and unmutated ighv
-
5:06
evolution of btk inhibitors in cll
-
32:11
prof follows' q and a session
-
4:05
comparing continuous and fixed duration therapy in cll
-
0:59
the impact of age and comorbidities on the outcomes of patients with cll treated with btk inhibitors
-
3:40
outcomes of all stratified by socioeconomic factors
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
1:01
cll resistance mechanisms in the era of novel agents
-
5:20
advances in the use of bispecific antibodies for the treatment of cll
-
1:20
improving patient outcomes in ctcl: clinical collaboration and novel agents
-
2:41
cell avidity as a predictor of t-cell efficacy
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
0:55
the impact of mrd & genetics on outcomes to time-limited combinations in patients with cll
-
0:56
analysis of outcomes of younger cll patients
-
1:35
ven-based regimens for r/r cll and considering an mrd-guided strategy